Literature DB >> 19712497

Surfactant replacement therapy in the neonate: beyond respiratory distress syndrome.

Steven M Donn1, Jennifer Dalton.   

Abstract

Surfactant-replacement therapy is a life-saving treatment for preterm infants with respiratory distress syndrome, a disorder characterized by surfactant deficiency. Repletion with exogenous surfactant decreases mortality and thoracic air leaks and is a standard practice in the developed world. In addition to respiratory distress syndrome, other neonatal respiratory disorders are characterized by surfactant deficiency, which may result from decreased synthesis or inactivation. Two of these disorders, meconium aspiration syndrome and bronchopulmonary dysplasia, might also be amenable to surfactant-replacement therapy. This paper discusses the use of surfactant-replacement therapy beyond respiratory distress syndrome and examines the evidence to date.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19712497

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  6 in total

Review 1.  Meconium-induced inflammation and surfactant inactivation: specifics of molecular mechanisms.

Authors:  Jana Kopincova; Andrea Calkovska
Journal:  Pediatr Res       Date:  2015-12-17       Impact factor: 3.756

2.  Synthetic liposomes are protective from bleomycin-induced lung toxicity.

Authors:  William M Gwinn; Mayanga C Kapita; Ping M Wang; Mark F Cesta; William J Martin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-05-20       Impact factor: 5.464

3.  Splitting of a three-dimensional liquid plug at an airway bifurcation.

Authors:  Hideki Fujioka; Francesco Romanò; Metin Muradoglu; James B Grotberg
Journal:  Phys Fluids (1994)       Date:  2022-08-22       Impact factor: 4.980

4.  Bronchopulmonary dysplasia - trends over three decades.

Authors:  Zofia Zysman-Colman; Genevieve M Tremblay; Suhair Bandeali; Jennifer S Landry
Journal:  Paediatr Child Health       Date:  2013-02       Impact factor: 2.253

5.  Expression of SP-C and Ki67 in lungs of preterm infants dying from respiratory distress syndrome.

Authors:  H Lu; W Li; G Shao; H Wang
Journal:  Eur J Histochem       Date:  2012-07-27       Impact factor: 3.188

6.  Impact of early surfactant and inhaled nitric oxide therapies on outcomes in term/late preterm neonates with moderate hypoxic respiratory failure.

Authors:  G G Konduri; G M Sokol; K P Van Meurs; J Singer; N Ambalavanan; T Lee; A Solimano
Journal:  J Perinatol       Date:  2013-07-18       Impact factor: 2.521

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.